Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 19/20 | 0.69 |
| ▸ | PIK3CD | O00329 | 7/20 | 0.69 |
| ▸ | PIK3CB | P42338 | 6/20 | 0.69 |
| ▸ | PIK3CG | P48736 | 6/20 | 0.69 |
| ▸ | GAK | O14976 | 1/20 | 0.50 |
| ▸ | PRKACG | P22612 | 1/20 | 0.50 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.50 |
| ▸ | MTOR | P42345 | 1/20 | 0.50 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 9/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30227352 | 0.91 | PIK3CA (0.63) | PIK3CAPIK3CDPIK3CBPIK3CGGAK | |
| SCHEMBL15803547 | 0.91 | PIK3CA (0.63) | PIK3CAPIK3CDPIK3CBPIK3CGGAK | |
| SCHEMBL24023242 | 0.90 | PIK3CA (0.56) | PIK3CAPIK3CDPIK3CBPIK3CGGAK | |
| SCHEMBL24023232 | 0.87 | PIK3CA (0.54) | PIK3CAPIK3CDPIK3CBPIK3CGGAK | |
| SCHEMBL28970637 | 0.86 | PIK3CA (0.53) | PIK3CAPIK3CDPIK3CBPIK3CGGAK | |
| SCHEMBL1889405 | 0.86 | PIK3CA (0.50) | PIK3CAPIK3CDPIK3CBPIK3CGGAK | |
| SCHEMBL24023246 | 0.84 | PIK3CA (0.48) | PIK3CAPIK3CDPIK3CBPIK3CGGAK | |
| SCHEMBL13469237 | 0.84 | PIK3CA (0.48) | PIK3CAPIK3CDPIK3CBPIK3CGGAK | |
| SCHEMBL1885511 | 0.84 | PIK3CD (0.47) | PIK3CAPIK3CDPIK3CBPIK3CGPI4KB | |
| SCHEMBL571448 | 0.82 | PIK3CG (0.71) | PIK3CAPIK3CDPIK3CBPIK3CGPI4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10328065-B2 | Pharmaceutical combination comprising the PI3K inhibitor alpelisib and the B-RAF inhibitor dabrafenib; the use of such combination in the treatment or prevention of cancer | NOVARTIS AG (CH) | 2019-06-25 | — | — | US | disclosed |
| US-10328066-B2 | Pharmaceutical combination comprising the PI3K inhibitor alpelisib and the CDK4/6 inhibitor ribociclib, and the use thereof in the treatment/prevention of cancer | NOVARTIS AG (CH) | 2019-06-25 | — | — | US | disclosed |
| WO-2017037578-A2 | COMBINATION THERAPY | NOVARTIS AG (CH) | 2017-03-09 | — | — | WO | disclosed |
| WO-2017037575-A1 | A PHARMACEUTICAL COMBINATION COMPRISING THE PI3K INHIBITOR ALPELISIB AND THE CDK4/6 INHIBITOR RIBOCICLIB, AND THE USE THEREOF IN THE TREATMENT/PREVENTION OF CANCER | NOVARTIS AG (CH) | 2017-03-09 | — | — | WO | disclosed |
| WO-2017037573-A1 | PHARMACEUTICAL COMBINATION COMPRISING THE PI3K INHIBITOR ALPELISIB AND THE B-RAF INHIBITOR DABRAFENIB; THE USE OF SUCH COMBINATION IN THE TREATMENT OR PREVENTION OF CANCER | NOVARTIS AG (CH) | 2017-03-09 | — | — | WO | disclosed |
| WO-2017037586-A1 | COMBINATION THERAPY USING PI3K INHBITOR AND MDM2 INHIBITOR | NOVARTIS AG (CH) | 2017-03-09 | — | — | WO | disclosed |
| EP-2331537-B1 | 1-((5-HETEROARYLTHIAZOL-2-YL)AMINOCARBONYL)PYRROLIDINE-2-CARBOXAMIDE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE (PI3K) INHIBITORS USEFUL IN THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2015-10-28 | — | — | EP | disclosed |
| US-9006270-B2 | Polymorphs of (S)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide | NOVARTIS AG (CH) | 2015-04-14 | — | — | US | disclosed |
| US-8980259-B2 | Combination therapy | NOVARTIS AG (CH) | 2015-03-17 | — | — | US | disclosed |
| US-8980259-B2 | Combination therapy | NOVARTIS AG (CH) | 2015-03-17 | — | — | US | disclosed |
| US-20140023661-A1 | COMBINATION THERAPY | AMGEN, INC. (US) | 2014-01-23 | — | — | US | disclosed |
| US-20140023661-A1 | COMBINATION THERAPY | AMGEN, INC. (US) | 2014-01-23 | — | — | US | disclosed |
| US-8476268-B2 | Pyrrolidine-1,2-dicarboxamide derivatives | NOVARTIS AG (CH) | 2013-07-02 | — | — | US | disclosed |
| WO-2012175522-A1 | POLYMORPHS OF (S)-PYRROLIDINE-1,2-DICARBOXYLIC ACID 2-AMIDE 1-({4-METHYL-5-[2-(2,2,2-TRIFLUORO-1,1-DIMETHYL-ETHYL)-PYRIDIN-4-YL]-THIAZOL-2-YL}-AMIDE | NOVARTIS AG (CH) | 2012-12-27 | — | — | WO | disclosed |
| US-8227462-B2 | Pyrrolidine-1,2-dicarboxamide derivatives | NOVARTIS AG (CH) | 2012-07-24 | — | — | US | disclosed |
| US-8227462-B2 | Pyrrolidine-1,2-dicarboxamide derivatives | NOVARTIS AG (CH) | 2012-07-24 | — | — | US | disclosed |
| WO-2012016970-A1 | A CRYSTALLINE FORM OF (S)-PYRROLIDINE-1,2-DICARBOXYLIC ACID 2-AMIDE 1-(4 -METHYL-5-[2-(2,2,2-TRIFLUORO-1,1-DIMETHYL-ETHYL)-PYRIDIN-4-YL]-THIAZOL-2-YL)-AMIDE AND ITS USE AS PI3K INHIBITOR | NOVARTIS AG (CH) | 2012-02-09 | — | — | WO | disclosed |
| US-20100105711-A1 | Organic Compounds | NOVARTIS AG | 2010-04-29 | — | — | US | disclosed |
| US-20100105711-A1 | Organic Compounds | NOVARTIS AG | 2010-04-29 | — | — | US | disclosed |
| WO-2010029082-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140023661-A1 | COMBINATION THERAPY | IGF1R, PIK3CA, ERBB2 | PIK3CA 2/4885PIK3CD 5/4885PIK3CB 15/4885 |
| US-10328066-B2 | Pharmaceutical combination comprising the PI3K inhibitor alpelisib and the CDK4/6 inhibitor ribociclib, and the use thereof in the treatment/prevention of cancer | CDK4, CDK6, CDK9 | PIK3CA 5/4885PIK3CD 15/4885PIK3CB 18/4885 |
| US-20100105711-A1 | Organic Compounds | PIK3C3, PIK3CA, PIK3CD | PIK3CA 2/4885PIK3CD 3/4885PIK3CB 6/4885 |
| US-10328065-B2 | Pharmaceutical combination comprising the PI3K inhibitor alpelisib and the B-RAF inhibitor dabrafenib; the use of such combination in the treatment or prevention of cancer | BRAF, RAF1, PIK3CA | PIK3CA 3/4885PIK3CD 12/4885PIK3CB 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.